A New Rapid In Vitro Assay for Assessing Reactivity of Acyl Glucuronides.
Idiosyncratic drug toxicity is a major challenge for the pharmaceutical industry since complex and multifactorial steps are involved, the dose-dependency is unclear, and its occurrence is not reliably predictable. Whereas the exact mechanisms leading to idiosyncratic toxicity remain elusive in many cases, there are often hints at the involvement of reactive metabolites, such as acyl glucuronides formed by conjugation of carboxylic acids with glucuronic acid. Because the patient-related susceptibilities leading to idiosyncratic toxicity are not sufficiently understood, the best option for the pharmaceutical industry is to minimize drug-related risk factors such as potential acyl glucuronide formation. Here, we describe a rapid in vitro assay for the assessment of the reactivity of acyl glucuronides, on the basis of acyl glucuronide migration, that can support the selection of low-risk drug candidates in the drug discovery phase. Twenty marketed compounds with a wide range of half-lives were tested, their acyl glucuronide migration rates were determined and compared with the half-lives of the respective acyl glucuronides. Ranking of acyl glucuronide stability using this method compared well with the results from existing methodologies. With this method, migration rates >20% would indicate higher risk of reactivity. This simpler approach using the acyl glucuronide migration rate is not dependent on authentic standards, therefore eliminating the requirement for either lengthy chemical synthesis or in vitro biosynthesis and purification of the 1-O-β-glucuronide. This methodology provides a rapid in vitro assay to assess acyl glucuronide stability and reactivity that is well suited for use early in the drug discovery phase.
Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China (S.Z., W.L., G.O.) and Roche Innovation Center Basel, Basel, Switzerland (R.J., S.S.).
Sheng
S
Zhong
Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China (S.Z., W.L., G.O.) and Roche Innovation Center Basel, Basel, Switzerland (R.J., S.S.).
Russell
R
Jones
Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China (S.Z., W.L., G.O.) and Roche Innovation Center Basel, Basel, Switzerland (R.J., S.S.).
Wenzhe
W
Lu
Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China (S.Z., W.L., G.O.) and Roche Innovation Center Basel, Basel, Switzerland (R.J., S.S.).
Simone
S
Schadt
Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China (S.Z., W.L., G.O.) and Roche Innovation Center Basel, Basel, Switzerland (R.J., S.S.) giorgio.ottaviani@roche.com.
Giorgio
G
Ottaviani
D000215:Acylation / Q000502:physiology; D000818:Animals; D002264:Carboxylic Acids / Q000378:metabolism* / Q000494:pharmacology; D002417:Cattle; D020719:Glucuronides / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D053719:Tandem Mass Spectrometry / Q000379:methods*; D013997:Time Factors
D002264:Carboxylic Acids; D020719:Glucuronides